The subgroup of the remaining KIT/PDGFRA WT GIST, but not SDH-deficient, have been further characterized: 4–13% carry a BRAF V600E mutation, are localized more frequently in small intestine and seem to have a more favourable prognosis [18–21]. Here, BRAF is linked to gastrointestinal stromal tumor.